Fecal Microbiota Transplantation for the Treatment of Nonalcoholic Fatty Liver Disease

Xue, Lan-Feng; Luo, Wen-hui; Wu, Li‐Hao; He, Xiaofu; Xia, Harry Hua‐Xiang; Chen, Yu

doi:10.14218/erhm.2018.00025

Cited by 7 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, a change in the microbiome of the offspring in case of maternal obesity or maternal obesogenic diet has been reported in preclinical models and the adult population. The gut microbiota in infants of obese mothers increased inflammation and susceptibility to MAFLD development [ 28 ]. The initial “pioneering” bacteria present in the gut appear to teach the immune system specifically innate immunity.…”

Section: General Information On Pediatric Mafldmentioning

confidence: 99%

Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem

et al. 2021

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MAFLD), previously called nonalcoholic fatty liver diseases (NAFLD), is one of the most important causes of chronic liver disease worldwide and will likely become the leading cause of end-stage liver disease in the decades ahead. MAFLD covers a continuum of liver diseases from fatty liver to nonalcoholic steatohepatitis (NASH), liver fibrosis/cirrhosis and hepatocellular cancer. Importantly, the growing incidence of overweight and obesity in childhood, 4% in 1975 to 18% in 2016, with persisting obesity complications into adulthood, is likely to be harmful by increasing the incidence of severe MAFLD at an earlier age. Currently, MAFLD is the leading form of chronic liver disease in children and adolescents, with a global prevalence of 3 to 10%, pointing out that early diagnosis is therefore crucial. In this review, we highlight the current knowledge concerning the epidemiology, risk factors and potential pathogenic mechanisms, as well as diagnostic and therapeutic approaches, of pediatric MAFLD.

show abstract

Section: General Information On Pediatric Mafldmentioning

confidence: 99%

Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 217 In contrast, another study involving a 3-day FMT infusion demonstrated a modest yet significant decrease in the severity of steatosis. 218 In a >12-month follow-up study by Bajaj et al , patients in the FMT arm showed sustained improvement in clinical and cognitive function parameters, with no recurrent hepatic encephalopathy occurrence and hospitalizations due to liver complications. 219 These findings highlight the variability in outcomes observed with FMT as a therapeutic approach for MAFLD up to this point.…”

Section: Resultsmentioning

confidence: 96%

Gut microbiota in MAFLD: therapeutic and diagnostic implications

Alghamdi,

Mosli,

Alqahtani

2024

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as nonalcoholic fatty liver disease, is becoming a significant contributor to chronic liver disease globally, surpassing other etiologies, such as viral hepatitis. Prevention and early treatment strategies to curb its growing prevalence are urgently required. Recent evidence suggests that targeting the gut microbiota may help treat and alleviate disease progression in patients with MAFLD. This review aims to explore the complex relationship between MAFLD and the gut microbiota in relation to disease pathogenesis. Additionally, it delves into the therapeutic strategies targeting the gut microbiota, such as diet, exercise, antibiotics, probiotics, synbiotics, glucagon-like peptide-1 receptor agonists, and fecal microbiota transplantation, and discusses novel biomarkers, such as microbiota-derived testing and liquid biopsy, for their diagnostic and staging potential. Overall, the review emphasizes the urgent need for preventive and therapeutic strategies to address the devastating consequences of MAFLD at both individual and societal levels and recognizes that further exploration of the gut microbiota may open avenues for managing MAFLD effectively in the future.

show abstract

“…One infusion was not associated with decreased liver steatosis in one study [ 83 ]. In another, a 3-day infusion induced a modest, although significant decrease in steatosis severity ( Table 3 ) [ 84 ].…”

Section: Interventional Studies Targeting the Microbiota In Mafldmentioning

confidence: 99%

Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?

Lanthier

Delzenne

2022

Cells

View full text Add to dashboard Cite

Numerous studies show a modification of the gut microbiota in patients with obesity or diabetes. Animal studies have also shown a causal role of gut microbiota in liver metabolic disorders including steatosis whereas the human situation is less clear. Patients with metabolic dysfunction associated fatty liver disease (MAFLD) also have a modification in their gut microbiota composition but the changes are not fully characterized. The absence of consensus on a precise signature is probably due to disease heterogeneity, possible concomitant medications and different selection or evaluation criteria. The most consistent changes were increased relative abundance of Proteobacteria, Enterobacteriaceae and Escherichia species and decreased abundance of Coprococcus and Eubacterium. Possible mechanisms linking the microbiota and MAFLD are increased intestinal permeability with translocation of microbial products into the portal circulation, but also changes in the bile acids and production of microbial metabolites such as ethanol, short chain fatty acids and amino acid derivatives able to modulate liver metabolism and inflammation. Several interventional studies exist that attempt to modulate liver disease by administering antibiotics, probiotics, prebiotics, synbiotics, postbiotics or fecal transplantation. In conclusion, there are both gaps and hopes concerning the interest of gut microbiome evaluation for diagnosis purposes of MAFLD and for new therapeutic developments that are often tested on small size cohorts.

show abstract

Fecal Microbiota Transplantation for the Treatment of Nonalcoholic Fatty Liver Disease

Cited by 7 publications

References 40 publications

Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem

Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem

Gut microbiota in MAFLD: therapeutic and diagnostic implications

Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?

Contact Info

Product

Resources

About